CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. Escola Paulista de Medicina (EPM) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Graduated in Medicine from the Faculdade de Ciências Médicas da Santa Casa de São Paulo (2001), medical residency in Neurology from the Federal Escola Paulista de Medicina - Universidade Federal de São Paulo (2006), PhD in science from the Escola Paulista de Medicina - Universidade Federal de São Paulo (2010), performed a Specialized Training Program in Multiple Sclerosis at the Multiple Sclerosis Center of Catalonia (Barcelona, Spain) (2011) and MBA in Health Economics and Management (2019). He served as assistant physician ]neurology emergency unit at Hospital São Paulo / Escola Paulista de Medicina - Universidade Federal de São Paulo from 2007 to 2013 and is currently Associated Professor in the Neurology Discipline at Escola Paulista de Medicina - Universidade Federal de São Paulo and an assistant physician in the Neuroimmunology and Demyelinating Diseases Clinic at UNIFESP. He is a member of the Brazilian Academy of Neurology, American Academy of Neurology and European Academy of Neurology serves in the scientific committee of the Guthy Jackson Charitable Foundation. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Introduction: Multiple Sclerosis (MS) is a demyelinating and autoimmune disease that affects the central nervous system (CNS), causing neurological disability due to inflammation and myelin and axonal injury. The first symptoms happen between 20 and 40 years of age with a relapsing-remitting or proggresive course. The main symptoms are paresthesia, weakness, visonloss, loss of control of…
Multiple Sclerosis (MS) is an autoimmune, inflammatory and demyelinating disease of the central nervous system, presenting a chronic evolution with periods of exacerbation throughout life. MS affects people at the peak of their productive life, between 20 and 40 years, and causes permanent neurological incapacity in the long term, thus being a potentially disabling disease that occurs in …
In the last decade, new drugs for multiple sclerosis have been tested and approved. Among them is natalizumab, that despite its high efficacy has its use limited by the risk of developing progressive multifocal leukoencephalopathy. By applying, a questionnaire with inclusion of patients diagnosed with relapsing-remitting multiple sclerosis, we aimed to assess how patients assess the risks…
| 3 / 3 | Completed scholarships in Brazil |
| Associated processes | |